Virology and Pathogenesis
Human T-cell lymphotropic virus type 1 (HTLV-1, also known as adult T-cell lymphoma virus type 1) belongs to the oncovirinae subfamily of human retroviruses. Like HIV, it targets CD4 + T cells. However, there are two critical differences in pathogenesis; firstly the replication rate is very high in HIV-1 infection, but low in HTLV-1 infection. Therefore compared to HIV-1, HTLV-1 has relatively low viral burden and high genetic stability. Secondly, while HIV-1 induces death of CD4 + T cells, HTLV-1 induces proliferation, and ultimately, transformation of infected CD4 + T cells. These differences partly explain the distinct spectrum of diseases caused by these two retroviruses.
Disease Association with HTLV-1 Infection
While most infected individuals remain asymptomatic, HTLV-1 may result in two major diseases, adult T-cell leukemia/lymphoma (ATLL) and HTLV- In contrast HAM/TSP is a slowly progressive disorder characterized by uni-or bilateral lower limb weakness and spasticity, lumbar pain and detrusor instability. The lifetime risk of HAM/TSP is estimated to be 0.25% in Japan 2 and 1.9% in Jamaica and Trinidad 4 . In a US prospective study, 3.7% of HTLV-1 carriers were diagnosed with HAM/TSP 5 .
HTLV-1-infected individuals with higher proviral load 6 The source of the virus is thought to be infected lymphocytes in breast milk, and proviral load in breast milk 11 or maternal blood 12 appears to contribute to milk-born transmission. A Jamaican study showed that MTCT occurred at 4.7 and 28.7 per 1,000 person months at low and high proviral loads in breast milk, respectively 11 .
Transmission of HTLV-1 infection to exclusively formula-fed infants indicates that other largely unknown routes of MTCT. Transplacental infection or placental microtransfusion is less likely, as proviral HTLV-1 DNA in cord blood of infected mothers is not indicative of intrauterine infection, and none of the cord blood samples derived from exclusive formula-fed HTLV-1 infected Japanese children contained HTLV-1 DNA 13 . Maternal saliva also contains proviral HTLV-1 DNA; however, natural activity and neutralizing antibody present in saliva appear to inhibit HTLV-1 transmission 14 .
Prevention of MTCT of HTLV-1
It is not possible to prevent the development of ATLL or other HTLV-1-associated disorders in HTLV-1 carriers and primary prevention is the only strategy likely to reduce disease. No HTLV-1 vaccine has reached clinical trials and therefore prevention is only achievable by restricting transmission. As the majority of HTLV-1 infection follows MTCT and ATLL develops only after MTCT, prevention of milk-born transmission is the most efficient and feasible way to reduce the disease burden.
Exclusive formula-feeding is the most reliable and easiest method to prevent milk-born infection, although the manifold advantages of breastfeeding would also be lost. An expected outcome of withholding breastfeeding is reduction of MTCT rate from 15-20% to 2-3%. Since lifetime risk of ATLL is approximately 5%, exclusive formula-feeding will reduce incidence of ATLL patients among individuals born from HTLV-1 carrier mothers from 0.75-1% to 0.1-0.15%. In contrast, breastfeeding can reduce infantile mortality rates for more than 20% in some developing countries 15 . Therefore, this preventive strategy may only be justified in developed country like Japan and even so is likely to be controversial.
There are two alternative methods to reduce breast milk HTLV-1 transmissionfreeze-thawing and reducing the duration of breast-feeding. Freeze-thawing effectively destroys HTLV-1-infected cells in breast milk in vitro and small-scale field studies demonstrated significant reduction of MTCT, 16 although it is laborious and may be impractical for many mothers. Expressed breast milk should be frozen at -20 o C or below for >12 h. MTCT can be reduced by limiting the duration of breastfeeding 10 . In Japan, seroconversion after 2 years of age is infrequent and most infected infants became seropositive by 12 months 9 17 . A prospective study in Jamaica showed that 32% of children breastfed for >12 months were infected, compared to 9% of those breastfed for <12 months (relative risk 3.4; 95% CI 1.7-6.9) 18 . An estimated median time of HTLV-1 infection in those children was 11.9 months 19 .
A number of small Japanese studies in Japan suggest that short-term breastfeeding (<3 months) was as effective as exclusive bottle-feeding in reducing MTCT of HTLV-1.
Current strategy in Japan to prevent MTCT of HTLV-1
Since 2011, it is recommended that all pregnant women in Japan are screened for HTLV-1
antibody by particle agglutination (PA) or chemiluminescent enzyme immunoassay (CLEIA),
with Western blotting and/or PCR for confirmation 20 . PA and CLEIA have high sensitivity and specificity, but still give a substantial number of false positive results, especially in non-endemic areas. Western blotting is also sometimes inconclusive. PCR is both sensitive and specific. Pregnant women with HTLV-1 infection receive detailed information about HTLV-1, MTCT and infant feeding strategies. Unless they give birth to high-risk infants (e.g., premature babies), they are advised to undertake either exclusive formula-feeding, freeze-thawing of expressed breast milk, or breastfeeding for a maximum of 3 months. Ongoing support is critical, especially for those who have chosen the latter two options. We recommend anti-HTLV-1 antibody testing of the offspring at three years of age 20 .
Perspectives in other endemic countries
HTLV-1 causes ATLL or HAM/TSP in only a minority of carriers after a long incubation period.
Withholding breastfeeding significantly reduces MTCT of HTLV-1, but will increase infantile mortality rate in developing countries and therefore the overall benefit is unclear. Long-term results from the current nationwide MTCT prevention program in Japan will be important in informing preventative strategies in other settings. 
